(PR-inside.com) BRISBANE, AUSTRALIA -- (Marketwire) -- 01/04/12 -- (ASX: ACL) -- Alchemia Limited is pleased to announce that the first patient in the pivotal Phase III clinical study of its lead cancer drug, HA-Irinotecan, was randomized on Dec 30, 2011 and has now received their first cycle of treatment. HA-Irinotecan is a novel drug formulation that uses Alchemia's HyACT technology to target the widely used chemotherapy drug irinotecan directly to cancer cells. The 390-patient Phase III study will compare the safety and effectiveness of HA-Irinotecan with irinotecan in a double blind trial in second and third line metastatic colorectal cancer patients ..

More...